Replies to post #6997 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

I did paint a broad stroke over the timeline for ALL the pending trials which I thought was rather aggressive. Your timeline is a lot more aggressive. The US FDA trial appears to be transparent with a start and end date. I'm unaware of any "speech" that points to a completed trial before Q1 2021. What I see as being a fuzzy gray area of all matters currently loaded in the cannon is - when might we get some data readouts? That's a timeline Dr. Mark Williams talked about in the BioPub webcast posted in the sticky notes. Doc said the study in South Korea can turn up data in the first 2 weeks of a 4 week trial. How that data will apply to the Australia and US clinical trials I don't know. There's a lot of moving parts all at once. Which is why Chris Moreau called the COVID-19 situation a game changer. It's a very compelling and accelerated story unfolding right before our eyes at Algernon. Do I think we will get some type of data readout in 2020 - Yes. Maybe from the Chronic Cough - Maybe from the COVID-19. Again, I just don't know, but certainly we can check the all the above box by Q1 2021 - Acute Lung Injury/Acute Respiratory Distress Syndrome (COVID-19), Chronic Cough, Idiopathic Pulminary Fibrosis...

March 19, 2020 - Algernon announces support of a physician initiated planned Phase 2 trial of Ifenprodil for COVID-19 in South Korea.

IMO, South Korea is the wild card here. If anyone got thoughts on it I'm all ears. I'm just saying I have no idea when that trial might start or when to expect data. In that instance it could apply to smoki's aggressive timeline for data - maybe summer or fall 2020.

Just 1 highly unscientific opinion,

/////AMG